Hyderabad: Suven Life Sciences Ltd on Wednesday said that it had been granted three product patents—one each by New Zealand, Singapore and South Korea—corresponding to new chemical entities for the treatment of neurodegenerative disorders, valid until 2029, 2030 and 2028, respectively.
“The granted claims of the patents include the class of selective...compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson’s and schizophrenia,” the Hyderabad-based company said in a statement.
Suven has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting neurodegenerative diseases in addition to developmental candidate SUVN-502 for Alzheimer’s disease and schizophrenia.
Products resulting from these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II trials, the company said.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, chief executive officer of Suven.
Shares of Suven were trading at Rs.45.10, up 3.32% on BSE at 3.30pm, while the benchmark Sensex was down 0.39% to 19,842.54 points.